HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine

被引：150

作者：

Joura, Elmar A. ^{[1
]}

Kjaer, Susanne K. ^{[2
]}

Wheeler, Cosette M. ^{[3
,4
]}

Sigurdsson, Kristjan ^{[5
]}

Iversene, Ole-Erik ^{[6
,7
]}

Hernandez-Avila, Mauricio ^{[8
]}

Perez, Gonzalo ^{[9
]}

Brown, Darron R. ^{[10
]}

Koutsky, Laura A. ^{[11
]}

Tay, Eng Hseon ^{[12
]}

Garcia, Patricia ^{[13
]}

Ault, Kevin A. ^{[14
]}

Garland, Suzanne M. ^{[15
,16
]}

Leodolter, Sepp

Olssonn, Sven-Eric ^{[17
]}

Tang, Grace W. K. ^{[18
]}

Ferris, Daron G. ^{[19
]}

Paavonen, Jorma ^{[20
]}

Lehtinen, Matti ^{[21
]}

Steben, Marc ^{[22
]}

Bosch, Xavier ^{[23
]}

Dillner, Joakim ^{[24
]}

Kurmanv, Robert J. ^{[25
,26
]}

Majewski, Slawomir ^{[27
]}

Munoz, Nubia ^{[28
]}

Myers, Evan R. ^{[29
]}

Villa, Luisa L. ^{[30
]}

Taddeo, Frank J. ^{[31
]}

Roberts, Christine ^{[31
]}

Tadesse, Amha ^{[31
]}

Bryan, Janine ^{[31
]}

Lupinaccia, Lisa C. ^{[31
]}

Giacoletti, Katherine E. D. ^{[31
]}

Lu, Shuang ^{[31
]}

Vuocolo, Scott ^{[31
]}

Hesley, Teresa M. ^{[31
]}

Haupt, Richard M. ^{[31
]}

Barr, Eliav ^{[31
]}

机构：

[1] Med Univ Vienna, AKH, Dept Obstet & Gynecol, Div Gynecol Oncol, A-1020 Vienna, Austria

[2] Rigshosp, Danish Canc Soc, Inst Canc Epidemiol, Dept Virus Hormones & Canc, DK-2100 Copenhagen, Denmark

[3] Univ New Mexico, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA

[4] Univ New Mexico, Dept Obstet & Gynaecol, Albuquerque, NM 87131 USA

[5] Natl Canc Detect Clin, Reykjavik, Iceland

[6] Haukeland Hosp, Dept Obstet & Gynecol, N-5021 Bergen, Norway

[7] Univ Bergen, Dept Clin Med, Bergen, Norway

[8] Inst Publ Hlth, Cuernavaca, Morelos, Mexico

[9] Univ Rosario, Bogota, Colombia

[10] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN USA

[11] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA

[12] KK Womens & Childrens Hosp, Singapore, Singapore

[13] Univ Peruana Cayetano Heredia, Epidemiol HIV & STD Unit, Lima, Peru

[14] Emory Univ, Sch Med, Dept Gynecol & Obstet, Atlanta, GA USA

[15] Univ Melbourne, Dept Obstet & Gynaecol, Melbourne, Vic, Australia

[16] Royal Hosp Women, Dept Microbiol & Infect Dis, Melbourne, Vic, Australia

[17] Danderyd Hosp, Karolinska Inst, Stockholm, Sweden

[18] Univ Hong Kong, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China

[19] Med Coll Georgia, Dept Family Med & Obstet & Gynecol, Augusta, GA 30912 USA

[20] Univ Cent Hosp, Dept Obstet & Gynaecol, Helsinki, Finland

[21] Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland

[22] Inst Natl Sante Publ Quebec, Direct Risques Biol Environnementaux & Occupation, Montreal, PQ, Canada

[23] IDIBELL, Inst Catala Oncol, Barcelona, Spain

[24] Lund Univ, Dept Med Microbiol, S-22100 Lund, Sweden

[25] Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Baltimore, MD 21205 USA

[26] Johns Hopkins Univ, Sch Med, Dept Pathol & Oncol, Baltimore, MD USA

[27] Warsaw Med Univ, Dept Dermatol & Venerol, Ctr Diagnost & Treatment Sexually Transmitted Dis, Warsaw, Poland

[28] Natl Canc Inst, Bogota, Colombia

[29] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA

[30] Ludwig Inst Canc Res, Dept Virol, Sao Paulo, Brazil

[31] Merck Res Labs, West Point, PA USA

来源：

VACCINE | 2008年 / 26卷 / 52期

关键词：

Human Papillomavirus; Humoral immunity; Immune memory;

D O I：

10.1016/j.vaccine.2008.09.073

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day I and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40% of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4%; 95% CI: 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：6844 / 6851

页数：8

共 31 条

[1] A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine [J].

Ault, KA ;

Giuliano, AR ;

Edwards, RP ;

Tamms, G ;

Kim, LL ;

Smith, JF ;

Jansen, KU ;

Allende, M ;

Taddeo, FJ ;

Skulsky, DM ;

Barr, E .

VACCINE, 2004, 22 (23-24) :3004-3007

[2]

BIEITBURD F, 1995, J VIROL, V69, P3959

[3] Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women [J].

Block, Stan L. ;

Nolan, Terry ;

Sattler, Carlos ;

Barr, Eliav ;

Giacoletti, Katherine E. D. ;

Marchant, Colin D. ;

Castellsague, Xavier ;

Rusche, Steven A. ;

Lukac, Suzanne ;

Bryan, Janine T. ;

Cavanaugh, Paul F., Jr. ;

Reisinger, Keith S. .

PEDIATRICS, 2006, 118 (05) :2135-2145

[4]

Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3

[5] POSTATTACHMENT NEUTRALIZATION OF PAPILLOMAVIRUSES BY MONOCLONAL AND POLYCLONAL ANTIBODIES [J].

CHRISTENSEN, ND ;

CLADEL, NM ;

REED, CA .

VIROLOGY, 1995, 207 (01) :136-142

[6] Human papillomavirus genotype distribution in low-grade cervical lesions: Comparison by geographic region and with cervical cancer. [J].

Clifford, GM ;

Rana, RK ;

Franceschi, S ;

Smith, JS ;

Gough, G ;

Pimenta, JM .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (05) :1157-1164

[7] A population-based study of squamous cell vaginal cancer: HPV and cofactors [J].

Daling, JR ;

Madeleine, MM ;

Schwartz, SM ;

Shera, KA ;

Carter, JJ ;

McKnight, B ;

Porter, PL ;

Galloway, DA ;

McDougall, JK ;

Tamimi, H .

GYNECOLOGIC ONCOLOGY, 2002, 84 (02) :263-270

[8] Optimization and validation of a multiplexed Luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18 [J].

Dias, D ;

Van Doren, J ;

Schlottmann, S ;

Kelly, S ;

Puchalski, D ;

Ruiz, W ;

Boerckel, P ;

Kessler, J ;

Antonello, JM ;

Green, T ;

Brown, M ;

Smith, J ;

Chirmule, N ;

Barr, E ;

Jansen, KU ;

Esser, MT .

CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2005, 12 (08) :959-969

[9] Clinical implications of human papillomavirus in head and neck cancers [J].

Fakhry, Carole ;

Gillison, Maura L. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (17) :2606-2611

[10] LATENT PAPILLOMAVIRUS AND RECURRING GENITAL WARTS [J].

FERENCZY, A ;

MITAO, M ;

NAGAI, N ;

SILVERSTEIN, SJ ;

CRUM, CP .

NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (13) :784-788

← 1 2 3 4 →